Patents Assigned to Novartis Finance Corporation
-
Patent number: 5891688Abstract: The present invention exploits the discovery that certain single base changes in the gacA gene coding sequence, which result in certain single amino acid changes in the encoded GacA protein, render it LemA-independent. The present invention therefore provides DNA that encodes mutant GacA proteins that do not require phosphorylation by LemA in order to be active as transcriptional activators.Type: GrantFiled: January 20, 1998Date of Patent: April 6, 1999Assignee: Novartis Finance CorporationInventors: Thomas D. Gaffney, Stephen T. Lam
-
Patent number: 5888801Abstract: The present invention is drawn to pesticidal strains and proteins. Bacillus strains which are capable of producing pesticidal proteins and auxiliary proteins during vegetative growth are provided. Also provided are the purified proteins, nucleotide sequences encoding the proteins and methods for using the strains, proteins and genes for controlling pests.Type: GrantFiled: June 6, 1995Date of Patent: March 30, 1999Assignee: Novartis Finance CorporationInventors: Gregory W. Warren, Martha A. Mullins, Annick J. de Framond
-
Patent number: 5889174Abstract: The present invention is drawn to pesticidal strains and proteins. Bacillus strains which are capable of producing pesticidal proteins and auxiliary proteins during vegetative growth are provided. Also provided are the purified proteins, nucleotide sequences encoding the proteins and methods for using the strains, proteins and genes for controlling pests.Type: GrantFiled: June 6, 1995Date of Patent: March 30, 1999Assignee: Novartis Finance CorporationInventors: Gregory W. Warren, Michael G. Koziel, Martha A. Mullins, Gordon J. Nye, Brian Carr, Nalini M. Desai, Kristy Kostichka, Juan J. Estruch
-
Patent number: 5882851Abstract: New cytochrome P-450 dependent monooxygenases and DNA molecules encoding these monooxygenases are provided, which are able to catalyze the biosynthetic pathway from amino acids to their corresponding cyanohydrins, the presursors of the cyanogenic glycosides, or to glucosinolates. Moreover, the invention provides methods for obtaining DNA molecules according to the invention and methods for obtaining transgenic plants resistant to insects, acarids, or nematodes or plants with improved nutritive value.Type: GrantFiled: August 8, 1996Date of Patent: March 16, 1999Assignees: Novartis Finance Corporation, Royal Veterinary Agricultural UniversityInventors: Birgit Maria Koch, Ole Sibbesen, Barbara Ann Halkier, Birger Lindberg M.o slashed.ller
-
Patent number: 5883283Abstract: The invention relates to a process for the preparation of substituted 3-amninobenzonitriles, which comprises reacting the appropriate substituted 3-aminochlorobenzene with a cyano-donating reagent, and to the compounds thereby produced. The compounds are intermediates, which after further reaction, produce 1,2,3-benzothiadiazole-derivatives having plant immunizing properties.Type: GrantFiled: August 1, 1997Date of Patent: March 16, 1999Assignee: Novartis Finance CorporationInventors: Richard Breitschuh, Benoit Pugin, Adriano Indolese, Verena Gisin
-
Patent number: 5880328Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: March 9, 1999Assignee: Novartis Finance CorporationInventors: John A. Ryals, Eric R. Ward, George B. Payne, Mary B. Moyer, Frederich Meins, Jr.
-
Patent number: 5880333Abstract: The present invention is drawn to a method of controlling gene expression in plants. Specifically, the method comprises obtaining a transgenic plant comprising at least two receptor expression cassettes and at least one target expression cassette. The first receptor expression cassette comprises a nucleotide sequence for a 5' regulatory region operably linked to a nucleotide sequence which encodes a first receptor polypeptide, and a 3' termination region. The second receptor expression cassette comprises a nucleotide sequence for a 5' regulatory region operably linked to a nucleotide sequence which encodes a second receptor polypeptide, and a 3' termination region.Type: GrantFiled: January 21, 1998Date of Patent: March 9, 1999Assignee: Novartis Finance CorporationInventors: Stephen A. Goff, Lyle D. Crossland, Laura S. Privalle
-
Patent number: 5877012Abstract: The present invention is drawn to a novel class of proteins, and their receptors. Novel processes, assays and methods for controlling plant pests are provided.Type: GrantFiled: April 3, 1997Date of Patent: March 2, 1999Assignee: Novartis Finance CorporationInventors: Juan J. Estruch, Cao-Guo Yu, Gregory W. Warren, Nalini M. Desai, Michael G. Koziel, Gordon J. Nye
-
Patent number: 5874106Abstract: Disclosed is a method of reducing crosslinking in gelatin capsules wherein an amino acid and a carboxylic acid are incorporated into the capsule fill, as well as filled gelatin capsules that utilize the disclosed method. The inventive method is especially useful for pharmaceutical formulations which include hydrochlorothiazide, triamterene, gemfibrozil, chloramphenicol, etodolac, piroxicam, nifedipine, tetracycline, diphenhydramine, hydroflumethiazide and rifampin, or a combination thereof as active ingredient.Type: GrantFiled: March 6, 1997Date of Patent: February 23, 1999Assignee: Novartis Finance CorporationInventors: Adedotun Tony Adesunloye, Paul Edward Stach
-
Patent number: 5872212Abstract: The present invention is drawn to pesticidal strains and proteins. Bacillus strains which are capable of producing pesticidal proteins and auxiliary proteins during vegetative growth are provided. Also provided are the purified proteins, nucleotide sequences encoding the proteins and methods for using the strains, proteins and genes for controlling pests.Type: GrantFiled: June 6, 1995Date of Patent: February 16, 1999Assignee: Novartis Finance CorporationInventors: Gregory W. Warren, Michael G. Koziel, Martha A. Mullins, Gordon J. Nye, Brian Carr, Nalini M. Desai, Kristy Kostichka
-
Patent number: 5869719Abstract: The present invention reveals that biotin biosynthesis in a plant is enhanced when the level of one or more of the enzymes in the plant biotin biosynthetic pathway is increased. Based upon this revelation, methods that increase the level of one or more biotin biosynthetic enzymes in plant tissue are provided as a means for achieving enhanced levels of biotin in plant tissue. In particular, a method is provided for enhancing biotin levels by introducing into plant tissue a chimeric gene capable of expressing a biotin biosynthetic enzyme such as biotin synthase. Thus, transgenic plant tissue, including whole plants, having enhanced levels of biotin is likewise provided.Type: GrantFiled: April 30, 1997Date of Patent: February 9, 1999Assignee: Novartis Finance CorporationInventor: David A. Patton
-
Patent number: 5866780Abstract: The present invention provides the nucleotide structure and organization of a novel maize chlorotic dwarf virus genome designated MCDV-Tn. Methods for using the complete or partial MCDV-Tn genomic sequence as a probe for diagnostic and other purposes are taught. Methods for inhibiting MCDV-Tn infection are also taught. These methods include the generation of transformed plants capable of expressing MCDV-Tn proteins, either in modified or unmodified form, and antisense sequences targeting MCDV-Tn genomic RNA. Recombinant production of MCDV-Tn proteins in appropriate host cells is also taught.Type: GrantFiled: April 4, 1995Date of Patent: February 2, 1999Assignee: Novartis Finance CorporationInventors: Marcus Law, Bradford B. Reddick, Ledare Habera
-
Patent number: 5866326Abstract: The present invention is drawn to pesticidal strains and proteins. Bacillus strains which are capable of producing pesticidal proteins and auxiliary proteins during vegetative growth are provided. Also provided are the purified proteins, nucleotide sequences encoding the proteins and methods for using the strains, proteins and genes for controlling pests.Type: GrantFiled: June 6, 1995Date of Patent: February 2, 1999Assignee: Novartis Finance CorporationInventors: Gregory W. Warren, Michael G. Koziel, Martha A. Mullins, Gordon J. Nye, Brian Carr, Nalini M. Desai, Kristy Kostichka, Nicholas B. Duck, Juan J. Estruch
-
Patent number: 5863951Abstract: The present invention relates to oxime ethers of general formula (I) and to their isomers and isomer mixtures which are possible in which (a) X is an N atom and Y is an oxygen atom or NH, or (b) X is CH and Y is an oxygen atom, in which furthermore R.sub.1 is C.sub.1 -C.sub.4 alkyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.4 alkyl cyclopropyl or cyano; R.sub.3 is cyano, substituted or unsubstituted C.sub.1 -C.sub.6 alkoxycarbonyl, substituted or unsubstituted di(C.sub.1 -C.sub.6 alkyl)aminocarbonyl, substituted or unsubstituted C.sub.1 -C.sub.6 alkyl-S(O).sub.n, substituted or unsubstituted aryl-S(O).sub.n, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl or substituted or unsubstituted heterocyclylcarbonyl; and R.sub.4 is C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.6 haloalkyl having 1 to 5 halogen atoms; C.sub.1 -C.sub.4 alkoxy-C.sub.1 -C.sub.2 alkyl; C.sub.2 -C.sub.6 alkenyl which is unsubstituted or substituted by 1 to 3 halogen atoms; C.sub.3 -C.sub.6 alkynyl; C.sub.3 -C.sub.Type: GrantFiled: April 3, 1997Date of Patent: January 26, 1999Assignee: Novartis Finance CorporationInventors: Hugo Ziegler, Stephan Trah, Rene Zurfluh
-
Patent number: 5859335Abstract: The present invention reveals that biotin biosynthesis in a plant is enhanced when the level of one or more of the enzymes in the plant biotin biosynthetic pathway is increased. Based upon this revelation methods which increase the level of one or more biotin biosynthetic enzymes in plant tissue are provided as a means for achieving enhanced levels of biotin in plant tissue. In particular, a method for enhancing biotin levels by introducing a chimeric gene capable of expressing a biotin biosynthetic enzyme into plant tissue is provided. Resulting transgenic plant tissue, including whole plants, having enhanced levels of biotin is also provided.Type: GrantFiled: March 8, 1995Date of Patent: January 12, 1999Assignee: Novartis Finance CorporationInventor: David Andrew Patton
-
Patent number: 5858745Abstract: Particularly effective B.t. insecticides are obtained by culturing to the sporulation stage novel transformant obtained on transforming B.t. kurstaki H.D. 562 with DNA expressing in the B.t. certain mutant endotoxin genes. Such transformants and other B.t. transformants generally may be obtained in high transformation frequencies by the electrotransformation of B.t. cells while in a hypertonic state followed by maintaining the cells in a hypertonic medium for a time sufficient to obtain intact cells. Transformation of B.t. tenebroinis and B.t. aizawai is also described.Type: GrantFiled: October 24, 1997Date of Patent: January 12, 1999Assignee: Novartis Finance CorporationInventors: Cindy Lou Jellis, Noah D. Beerman, Jean-Christophe Piot
-
Patent number: 5856154Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: January 5, 1999Assignee: Novartis Finance CorporationInventors: John A. Ryals, Danny C. Alexander, Robert M. Goodman, Eric R. Ward
-
Patent number: 5851766Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: December 22, 1998Assignee: Novartis Finance CorporationInventors: John A. Ryals, Christian Harms
-
Patent number: 5849870Abstract: The present invention is drawn to pesticidal strains and proteins. Bacillus strains which are capable of producing pesticidal proteins and auxiliary proteins during vegetative growth are provided. Also provided are the purified proteins, nucleotide sequences encoding the proteins and methods for using the strains, proteins and genes for controlling pests.Type: GrantFiled: June 5, 1995Date of Patent: December 15, 1998Assignee: Novartis Finance CorporationInventors: Gregory W. Warren, Michael G. Koziel, Martha A. Mullins, Gordon J. Nye, Brian Carr, Nalini M. Desai, Kristy Kostichka, Nicholas B. Duck, Juan J. Estruch
-
Patent number: 5849911Abstract: There are described compounds of formula I*, ##STR1## wherein R.sub.1 is lower alkoxycarbonyl,R.sub.2 is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl,R.sub.3 is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C.sub.4 -C.sub.8 cycloalkyl,R.sub.4 is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom, has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen, oxygen, sulfur, sulfinyl (--SO--) and sulfonyl (--SO.sub.2 --) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl,R.sub.5, independently of R.sub.2, has one of the meanings mentioned for R.sub.2, andR.sub.6, independently of R.sub.1, is lower alkoxycarbonyl,or salts thereof, provided that at least one salt-forming group is present.The compounds are inhibitors of retroviral aspartate protease and can be used, for example, in the treatment of AIDS.Type: GrantFiled: April 9, 1997Date of Patent: December 15, 1998Assignee: Novartis Finance CorporationInventors: Alexander Fassler, Guido Bold, Hans-Georg Capraro, Marc Lang, Satish Chandra Khanna